TABLE 1.
Nanodiscs type |
Inserted | Applications | References |
---|---|---|---|
MSP nanodiscs | Hydrophobic drugs&Cabazitaxel | Cancer chemotherapy | Pandey et al. (2021) |
MSP nanodiscs (Lipids modified) | — | Antibody-conjugated NDs for targeted cancer imaging | Wong et al. (2020) |
MSP nanodiscs | Influenza virus M2 protein | Antibody Discovery | Yu et al. (2023) |
apoA I-stabilized Nanodiscs (like MSP nanodiscs) | Amphotericin B | Anti-fungal drug delivery | Cho et al. (2017) |
ApoJ-stabilized Nanodiscs (like MSP nanodiscs) | — | Alzheimer’s disease treatment | Fernandez-de-Retana et al. (2017) |
Peptide nanodiscs | Adpgk & CM9 peptides | Cancer vaccine | Najafabadi et al. (2021) |
Peptide nanodiscs | DTX/CpG | ICD inducer | Kadiyala et al. (2019) |
Peptide nanodiscs (KT peptide modified) | T0901317 | LXR agonist for diabetic nephropathy | He et al. (2022) |
Peptide nanodiscs | ML355 | Antiplatelet drug | He et al. (2020) |
SMA nanodiscs | Bacterial Outer Membrane | Antibacterial Vaccination | Noh et al. (2022) |
CBZ, cabazitaxel; DTX, docetaxel; KT, kidney targeting; ICD, immunogenic cell death.